The notices it replaced
- Reissues: PAR-21-029 Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
- 2 steps back: PAR-17-336 Discovery of in vivo Chemical Probes for Novel Brain Targets (R01)
- 3 steps back: PAR-14-279 Discovery of in vivo Chemical Probes (R01)
- 4 steps back: PAR-12-060 Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes (R01)
Replaced by PAR-27-081.
Who won it before
58 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $38,291,892 in first-year total cost, median $581,982.
Most frequent study sections
- Special Emphasis Panel[ZRG1 MDCN-C (58)]38
- Drug Discovery for the Nervous System Study Section[DDNS]12
- Drug Discovery and Molecular Pharmacology B Study Section[DMPB]4
- Special Emphasis Panel[ZRG1-MDCN-C(58)R]2
- Molecular and Cellular Neuropharmacology Study Section [MCNP]1
Most frequent institutions
- VANDERBILT UNIVERSITY7
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE4
- UNIV OF NORTH CAROLINA CHAPEL HILL4
- MASSACHUSETTS GENERAL HOSPITAL3
- RESEARCH TRIANGLE INSTITUTE3
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Regulation of metabotropic glutamate receptor activity by protein/protein interactions1R01MH136164-01A1 | NISWENDER, COLLEEN M | VANDERBILT UNIVERSITY, TN | $396,250 | MCNP |
| 2024 | Optimization of a potent and cell active CK2 chemical probe for Alzheimer's disease therapy1R56AG084730-01A1 · under PAR-21-029 | AXTMAN, ALISON DONNELLY | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $833,173 | DMPB |
| 2024 | Development of sterol carrier protein 2 inhibitors as anxiolytics1R01MH133315-01A1 · under PAR-21-029 | CUNNINGHAM, CHRISTOPHER WHILLARD, CECILIA JLIEDHEGNER, ELIZABETH S | MEDICAL COLLEGE OF WISCONSIN, WI | $679,286 | DMPB |
| 2024 | In Vivo Probes of Mas1 Receptor1R01MH135136-01 · under PAR-21-029 | MAITRA, RANGANRUNYON, SCOTT P | RESEARCH TRIANGLE INSTITUTE, NC | $636,641 | DMPB |
| 2023 | BET-BD1 Selective Neuroimaging probes for Alzheimer's disease research1RF1AG081195-01 · under PAR-21-029 | WANG, CHANGNINGZHANG, CAN MARTIN | MASSACHUSETTS GENERAL HOSPITAL, MA | $2,442,345 | DDNS |
| 2023 | Probing neuroinflammation in Alzheimer's disease with NLRP3 PET radiotracers1RF1AG076912-01A1 · under PAR-21-029 | ZHANG, SHIJUN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $1,889,973 | DDNS |
| 2023 | Small-molecule probes for augmenting D5 receptor signaling1R01MH132019-01 · under PAR-21-029 | BARROW, JAMESCARR, GREGORY V | LIEBER INSTITUTE, INC., MD | $837,713 | DDNS |
| 2023 | Probing brain circuit and behavior with protein:protein interaction modulators1R01MH132226-01 · under PAR-21-029 | LAEZZA, FERNANDAZHOU, JIA | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $824,232 | DDNS |
| 2023 | Structure-based Design of Selective Serotonin Biased Agonists as Chemical Probes for Psychedelic Potential1R01MH133849-01 · under PAR-21-029 | MCCORVY, JOHN D | MEDICAL COLLEGE OF WISCONSIN, WI | $530,972 | DMPB |
| 2022 | Development of in vivo probes to study the function of TRIP8b in cognition1R56MH128747-01A1 · under PAR-21-029 | CHETKOVICH, DANE MSCHILTZ, GARY E | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $847,526 | DDNS |
| 2021 | Development of PET imaging probes for ROCK21R01AG069921-01 · under PAR-17-336 | CAI, ZHENGXIN | YALE UNIVERSITY, CT | $836,532 | DDNS |
| 2021 | Characterization of an 18F COX-2 PET ligand for in vivo brain imaging1R01AG070042-01 · under PAR-17-336 | PRABHAKARAN, JAYA | NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC, NY | $476,564 | DDNS |
| 2020 | Novel allosteric activation of nicotinamide rescue1RF1AG067771-01 · under PAR-17-336 | THATCHER, GREGORY R. J | UNIVERSITY OF ARIZONA, AZ | $2,264,368 | DDNS |
| 2020 | Small molecule antagonist probes for the relaxin-3/RXFP3 system1R01AA028255-01 · under PAR-17-336 | BESHEER, JOYCEJIN, CHUNYANG | RESEARCH TRIANGLE INSTITUTE, NC | $594,334 | DDNS |
| 2019 | Lead optimization of novel CRFBP-CRFR2 complex modulators for alcohol use disorder1R01AA026589-01A1 · under PAR-17-336 | SHEFFLER, DOUGLAS J | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $865,843 | DDNS |
| 2019 | In vivo Probe for ionotropic glutamate signaling system: AMPA receptors1R01MH120197-01 · under PAR-17-336 | LIANG, STEVEN H | MASSACHUSETTS GENERAL HOSPITAL, MA | $719,969 | DDNS |
| 2019 | Evaluation Of Trk Probes In Models For Dry Eye Disease1R01EY029695-01 · under PAR-17-336 | BURGESS, KEVIN | TEXAS A&M UNIVERSITY, TX | $489,413 | DDNS |
| 2018 | Targeting RIPK3 in Age-Related Inflammation and Injury1R56AG058642-01 · under PAR-14-279 | BALACHANDRAN, SIDDHARTHCUNY, GREGORY DDEGTEREV, ALEXEI | TUFTS UNIVERSITY BOSTON, MA | $648,995 | ZRG1 |
| 2018 | Development of NLRP3 inflammasome inhibitors towards Alzheimer's disease1R01AG058673-01 · under PAR-14-279 | SUN, DONGWANG, XIANG-YANG SHAWNZHANG, SHIJUN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $609,347 | ZRG1 |
| 2018 | Expanding the Chemical Biology of K2P Channels with Selective Cellular and In vivo Probes1R01MH116278-01 · under PAR-14-279 | MINOR, DANIEL LRENSLO, ADAM R | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $488,166 | ZRG1 |
| 2018 | DISCOVERY OF IN VIVO CHEMICAL PROBES FOR POLYCOMB CBX DOMAINS1R01CA218392-01A1 · under PAR-14-279 | FRYE, STEPHEN VERNON | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $456,482 | ZRG1 |
| 2017 | Creation of in vivo active chemical probes for CAMKK2 to treat cancer1R01CA218442-01 · under PAR-14-279 | DREWRY, DAVID HAROLD | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $691,617 | ZRG1 |
| 2017 | Isozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to Chemotherapy1R01CA214567-01 · under PAR-14-279 | BUCKANOVICH, RONALD JLARSEN, SCOTT D | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $636,181 | ZRG1 |
| 2017 | Chemical Inhibitors of 15-prostaglandin dehydrogenase Potentiate Hematopoietic Stem Cell Transplantation1R01CA216863-01 · under PAR-14-279 | GERSON, STANTON L.MARKOWITZ, SANFORD D.READY, JOSEPH M | UT SOUTHWESTERN MEDICAL CENTER, TX | $520,706 | ZRG1 |
| 2017 | USP7 inhibitors for the treatment of multiple myeloma1R01CA211681-01 · under PAR-14-279 | BUHRLAGE, SARA J | DANA-FARBER CANCER INST, MA | $504,721 | ZRG1 |
| 2017 | Development of a Selective Metabotropic Glutamate Receptor 7 Allosteric Modulator Probe1R01MH113543-01 · under PAR-14-279 | LINDSLEY, CRAIGNISWENDER, COLLEEN M | VANDERBILT UNIVERSITY, TN | $400,356 | ZRG1 |
| 2017 | Non-Covalent Nrf2 Activators for the Treatment of Chronic Wounds1R01AR069541-01A1 · under PAR-14-279 | MOORE, TERRY WILLIAM | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $347,552 | ZRG1 |
| 2016 | Discovery of probes that enhance expression of the neuroprotective protein Klotho1R56AG051638-01A1 · under PAR-14-279 | ABRAHAM, CARMELA RHODGETTS, KEVIN | BOSTON UNIVERSITY MEDICAL CAMPUS, MA | $855,556 | ZRG1 |
| 2016 | Lead optimization of novel ML-IAP antagonists to treat lung cancer1R01CA195227-01A1 · under PAR-14-279 | COSFORD, NICHOLAS DAVIDFINLAY, DARREN | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $808,701 | ZRG1 |
| 2016 | NPQ/Spexin the Endogenous Ligand for the Galanin Receptor 31R01DA040882-01A1 · under PAR-14-279 | OZAWA, AKIHIKOTOLL, LAWRENCE R | TORREY PINES INST FOR MOLECULAR STUDIES, FL | $742,361 | ZRG1 |
| 2016 | Optimization of glucocorticoid receptor (GR) passive antagonists for the treatment of post-traumatic stress disorder (PTSD)1R01MH109655-01 · under PAR-14-279 | JACKSON, MICHAELPINKERTON, ANTHONY BRUCE | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $611,804 | ZRG1 |
| 2016 | Discovery of in vivo small molecules for hearing protection against cisplatin and noise1R01DC015444-01 · under PAR-14-279 | ZUO, JIAN | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $595,909 | ZRG1 |
| 2016 | Optimization of S1P3 antagonists for fibrotic disease1R01AR069877-01 · under PAR-14-279 | ROSEN, HUGH | SCRIPPS RESEARCH INSTITUTE, THE, CA | $592,901 | ZRG1 |
| 2016 | ERRgamma Agonists to Treat Muscular Dystrophy1R01AR069280-01A1 · under PAR-14-279 | BURRIS, THOMAS PWALKER, JOHN K. | SAINT LOUIS UNIVERSITY, MO | $580,666 | ZRG1 |
| 2016 | Microbiome-Targeted Probes to Eliminate Chemotherapy-Induced GI Toxicity1R01CA207416-01 · under PAR-14-279 | REDINBO, MATTHEW R | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $552,404 | ZRG1 |
| 2016 | Development of an mGlu2/4 heterodimer-selective allosteric modulator1R01MH108498-01 · under PAR-14-279 | LINDSLEY, CRAIGNISWENDER, COLLEEN M | VANDERBILT UNIVERSITY, TN | $516,805 | ZRG1 |
| 2016 | Optimization of RORgamma-specific agonists as immune activators for a new immunotherapy approach for cancer1R01CA206493-01 · under PAR-14-279 | GRIFFIN, PATRICK ROBERTKAMENECKA, THEODORE M | SCRIPPS FLORIDA, FL | $439,200 | ZRG1 |
| 2016 | Optimization of ERRg-specific ligands as in vivo Chemical Probes1R01HD087046-01 · under PAR-14-279 | GRIFFIN, PATRICK ROBERTKAMENECKA, THEODORE M | SCRIPPS FLORIDA, FL | $398,400 | ZRG1 |
| 2015 | Discovery of Chemical Probes for RNA-Binding Protein Host Defense Factors1R01GM110119-01A1 · under PAR-12-060 | SMITH, HAROLD C | OYAGEN, INC., NY | $601,514 | ZRG1 |
| 2015 | Probes to target the 3-way hotspot of IL1RacP to abolish aberrant interleukin inflammation1R01AR068436-01 · under PAR-14-279 | LIOTTA, LANCE ALLEN | GEORGE MASON UNIVERSITY, VA | $595,160 | ZRG1 |
| 2015 | Development of a Novel Inducer for EBV Lytic Therapy1R01CA193624-01 · under PAR-12-060 | KENNEY, SHANNON CELESTELIEBERMAN, PAUL M.SALVINO, JOSEPH M | WISTAR INSTITUTE, PA | $591,954 | ZRG1 |
| 2015 | Development of an In Vivo, Brain-penetrant GIRK1/2 Potassium Channel Activator1R01MH107399-01 · under PAR-14-279 | HOPKINS, COREY R.WEAVER, C DAVIDWICKMAN, KEVIN D | VANDERBILT UNIVERSITY, TN | $583,297 | ZRG1 |
| 2015 | Small molecule CXCR4 modulators as molecular probes for studying AML1R01CA189074-01A1 · under PAR-14-279 | MILLER, RICHARD JPLATANIAS, LEONIDAS C.SCHILTZ, GARY E | NORTHWESTERN UNIVERSITY, IL | $529,121 | ZRG1 |
| 2015 | Partial Agonists at Estrogen Receptor alpha for Breast Cancer Therapy1R01CA188017-01A1 · under PAR-12-060 | THATCHER, GREGORY R. J | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $485,489 | ZRG1 |
| 2015 | Development of RORbeta-selective modulators as in vivo probes1R01MH108173-01 · under PAR-14-279 | GRIFFIN, PATRICK ROBERTKAMENECKA, THEODORE M | SCRIPPS FLORIDA, FL | $480,000 | ZRG1 |
| 2015 | Small molecule in vivo probe development targeting the IL-6/STAT3 pathway for potential multiple sclerosis therapy1R01NS088437-01A1 · under PAR-12-060 | LI, CHENGLONGYANG, YUHONG | OHIO STATE UNIVERSITY, OH | $471,114 | ZRG1 |
| 2015 | Chemical Probes for In Vivo Fibrin Imaging1R01CA197401-01 · under PAR-14-279 | ZHANG, ZHAODA | MASSACHUSETTS GENERAL HOSPITAL, MA | $466,961 | ZRG1 |
| 2015 | Discovery of mAChR5 Modulators for Use in Rodent Models of Drug Addiction1R01DA037207-01A1 · under PAR-12-060 | JONES, CARRIE KIMBERLYLINDSLEY, CRAIG | VANDERBILT UNIVERSITY, TN | $353,142 | ZRG1 |
| 2014 | Lead Optimization of Novel Inhibitors of the Thioesterase Domain of FASN1R01CA188694-01 · under PAR-12-060 | COSFORD, NICHOLAS DAVIDSMITH, JEFFREY W | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $755,282 | ZRG1 |
| 2014 | Inhibition of the Rho/MRTF/SRF Pathway as a New Treatment for Systemic Sclerosis1R01AR066049-01 · under PAR-12-060 | LARSEN, SCOTT D | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $655,452 | ZRG1 |
| 2014 | Development and Application of Selective Covalent Cdk7 Inhibitors1R01CA179483-01A1 · under PAR-12-060 | GRAY, NATHANAEL SCHIANDERMITSIADES, CONSTANTINE S. | DANA-FARBER CANCER INST, MA | $505,961 | ZRG1 |
| 2014 | Discovering Novel Atypical PKC Inhibitors as in vivo Chemical Probes1R01EY023725-01A1 · under PAR-12-060 | ANTONETTI, DAVID | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $499,870 | ZRG1 |
| 2014 | Optimization of non-peptide probes for the NPFF receptor system1R01DA034777-01A1 · under PAR-12-060 | MCCURDY, CHRISTOPHER R | UNIVERSITY OF MISSISSIPPI, MS | $498,705 | ZRG1 |
| 2014 | Discovery of Potent 12-Lipoxygenase Inhibitors of Platelet Activation1R01AG047986-01 · under PAR-12-060 | HOLMAN, THEODORE R | UNIVERSITY OF CALIFORNIA SANTA CRUZ, CA | $496,455 | ZRG1 |
| 2014 | Small molecules modulating RNA-binding protein Msi11R01CA178831-01A1 · under PAR-12-060 | AUBE, JEFFREYNEUFELD, KRISTI LXU, LIANG | UNIVERSITY OF KANSAS LAWRENCE, KS | $432,491 | ZRG1 |
| 2014 | In vivo probes for the APJ receptor.1R01HD079547-01A1 · under PAR-12-060 | MAITRA, RANGANRUNYON, SCOTT P | RESEARCH TRIANGLE INSTITUTE, NC | $427,829 | ZRG1 |
| 2014 | Optimization of modulators of Gbg-SNARE interaction1R01MH101679-01A1 · under PAR-12-060 | HAMM, HEIDI ESTAUFFER, SHAUN R | VANDERBILT UNIVERSITY, TN | $400,752 | ZRG1 |
| 2014 | Allosteric modulators of the glucagon-like peptide-1 receptor1R01GM106232-01A1 · under PAR-12-060 | DANIELS, JOHN SCOTTLINDSLEY, CRAIGNISWENDER, KEVIN D | VANDERBILT UNIVERSITY, TN | $297,379 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.